Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan 1;21(1):348-58.
doi: 10.1016/j.bmc.2012.10.034. Epub 2012 Oct 29.

Novel route to chaetomellic acid A and analogues: serendipitous discovery of a more competent FTase inhibitor

Affiliations

Novel route to chaetomellic acid A and analogues: serendipitous discovery of a more competent FTase inhibitor

Franco Bellesia et al. Bioorg Med Chem. .

Abstract

A new practical route to chaetomellic acid A (ACA), based on the copper catalysed radical cyclization (RC) of (Z)-3-(2,2-dichloropropanoyl)-2-pentadecylidene-1,3-thiazinane, is described. Remarkably, the process entailed: (i) a one-pot preparation of the intermediate N-α-perchloroacyl-2-(Z)-alkyliden-1,3-thiazinanes starting from N-(3-hydroxypropyl)palmitamide, (ii) a two step smooth transformation of the RC products into ACA and (iii) only one intermediate chromatographic purification step. The method offers a versatile approach to the preparation of ACA analogues, through the synthesis of an intermediate maleic anhydride with a vinylic group at the end of the aliphatic tail, a function that can be transformed through a thiol-ene coupling. Serendipitously, the disodium salt of 2-(9-(butylthio)nonyl)-3-methylmaleic acid, that we prepared as a representative sulfurated ACA analogue, was a more competent FTase inhibitor than ACA. This behaviour was analysed by a molecular docking study.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chaetomellic acid A (1).
Figure 2
Figure 2
Structural similarity between the dianionic form of chaetomellic acid A 2 and farnesyl pyrophosphate (FPP).
Figure 3
Figure 3
Sodium maleates used in the FTase assays.
Figure 4
Figure 4
Structure of the ACA analogues 29 and 30, and their IC50 values against yeast FTase.
Figure 5
Figure 5
a) Alignment of FPP, in the conformation assumed in the 1FT2 pdb structure (blue), FPT-II FPP, in the conformation assumed in the 1TN8 pdb structure (yellow), and of the thia-analogue 27 in the quasi-extended conformation chosen (atom colors: carbon atoms are in green, oxygen atoms in red, and sulfur atom in orange). b) Superposition of the molecular volume of 27 (green) and the volume of the supermolecule (white) formed by FPP and FPT-II FPP. In the figure the hydrogen atoms are omitted for clarity.
Figure 6
Figure 6
The interaction of inhibitor 27 and the FTase binding site. The enzyme α-subunit is represented in grey, the β-subunit is represented in yellow. Aminoacid residues involved in the interations are colored by element type (grey: carbon, blue: nitrogen, red: oxygen). Compound 27 is represented according to the color code of Figure 5. The hydrogen atoms are not displayed for clarity. Top: focus on the interactions of the anionic head of 27 with the FTase binding site; bottom: focus on the interactions established by the hydrophobic tail of compound 27; inset: an overall view of the ternary complex FTase-27-peptide (CVLS).
Scheme 1
Scheme 1
pH dependent equilibrium between the active dianionic open form 2 and the anhydride chaetomellic A (3).
Scheme 2
Scheme 2
(a) 1) (COCl)2, CH2Cl2, DMF, 23 °C, 2 h; 2) N-benzyl-3-Cl-2-propenylamine (PG1 = Bn) or 2-(3-chloro-2-propenylamino)pyridine (PG2 = 2-Py), Py, 23 °C, 1 h. (b) CuCl-TMEDA, CH3CN, argon, 60 °C, 20 h. (c) 1) Na0, CH3OH/diethyl ether, 25 °C, 20 h; 2) H+/H2O. (d) 1) KOH, CH3OH/THF, reflux, 2 h; 2) H+/H2O. (e) 1) Na0, CH3OH/diethyl ether, 25 °C, 20 h; 2) H2SO4 4 N, 110 °C, 2 h.
Scheme 3
Scheme 3
(a) CuCl-TMEDA, toluene, argon, 60 °C, 24 h. (b) Na0, toluene/MeOH, 25 °C, 24 h. (c) H2SO4/H2O, 110 °C, 3 h. (d) One-pot procedure: 1) Na0, toluene/MeOH, 25 °C, 24 h; 2) H2SO4/H2O, 110 °C, 3 h. (e) MnO2, CH2Cl2, 25 °C, 20 h. (f) H2SO4/H2O, 110 °C, 4 h.
Scheme 4
Scheme 4
Possible mechanism for the RC of N-α-perchloroacyl six membered cyclic ketene-N, S-acetals A.
Scheme 5
Scheme 5
Preparation of the 3,4-disubstituted-2,5-furandiones: (a) CuCl (5 mol%), TMEDA (10 mol%), CH3CN, Na2CO3, argon, 17 h, 30 °C; (b) silica-sulfuric acid, NaNO3, SiO2/H2O 3:2, CH2Cl2, 45 °C, 40 h; (c) KOH, CH3OH-THF, reflux 2 h; (d) HCl (10 %), r.t..
Scheme 6
Scheme 6
Preparation of the N-2,2-dichloropropanoyl ketene-N,S-acetal 10.
Scheme 7
Scheme 7
Reactions of the N-2,2-dichloropropanoyl ketene-N,S-acetal 10: (a) CuCl (10 mol%), TMEDA (20 mol%), CH3CN/toluene (3/2), Na2CO3, argon, 30 °C, 19–24 h; (b) KI, H2O, r.t., 24 h; (c) NaOH, THF/H2O, r. t., 12h, acidic work-up.
Scheme 8
Scheme 8
Possible mechanism for deprotection of the thioacetal moiety in 12.
Scheme 9
Scheme 9
Preparation of anhydride 18: (a) P4S10/HMDO, CH2Cl2, reflux, 5h; (b) 150 °C, 2 h, under vacuum; (c) CH3CCl2COCl, Py, CH2Cl2, 0–25°C, 20 h; (d) CuCl (10 mol%), TMEDA (20 mol%), CH3CN/toluene (3/2), Na2CO3, argon, 30 °C, 19–24 h; (e) i) KI, H2O, 24 h, ii) NaOH, THF/H2O, r. t., 12h, acidic work-up.
Scheme 10
Scheme 10
Radical addition of butanethiol to the terminal C=C group of 18.
Scheme 11
Scheme 11
Preparation of anhydride 19: (a) P4S10/HMDO, CH2Cl2, reflux, 5h; (b) 150 °C, 2 h, under vacuum; (c) CH3CCl2COCl, Py, CH2Cl2, 0–25°C, 20 h; (d) i) CuCl (10 mol%), TMEDA (20 mol%), CH3CN/toluene (3/2), Na2CO3, argon, 30 °C, 19–24 h, ii) KI, H2O, r.t., 24 h, iii) NaOH, THF/H2O, r. t., 12h, acidic work-up.

Similar articles

Cited by

References

    1. Leonard DM. J Med Chem. 1997;40:2971–2990. - PubMed
    2. Beck LA, Hosick TJ, Sinensky M. J Cell Biol. 1988;107:1307–1316. - PMC - PubMed
    3. Wolda SL, Glomset JA. J Biol Chem. 1988;263:5997–6000. - PubMed
    4. Lane KT, Beese LS. J Lipid Res. 2006;47:681–699. - PubMed
    5. Winter-Vann AM, Casey PJ. Nat Rev Cancer. 2005;5:405–412. - PubMed
    1. Anderegg RJ, Betz R, Carr SA, Crabb JW, Duntze W. J Biol Chem. 1988;263:18236–18240. - PubMed
    2. Farnsworth CC, Wolda CL, Gelb MH, Glomset JA. J Biol Chem. 1989;264:20422–20429. - PMC - PubMed
    3. Casey PJ, Solski PA, Der CJ, Buss JE. Proc Natl Acad Sci USA. 1989;86:8323–8327. - PMC - PubMed
    4. Maltese WA, Robishaw JD. J Biol Chem. 1990;265:18071–18074. - PubMed
    5. Fukada Y, Takao T, Ohguru H, Yoshizawa T, Akino T, Shimonishi Y. Nature (London) 1990;346:658–660. - PubMed
    6. Lai RK, Perez-Sala D, Canada FJ, Rando RR. Proc Natl Acad Sci USA. 1990;87:7673–7677. - PMC - PubMed
    7. Moores SL, Schaber MD, Mosser SD, Rands E, O'Hara MB, Garsky VM, Marshall MS, Pompliano DL, Gibbs JB. J Biol Chem. 1991;266:14603–14610. - PubMed
    1. Chow M, Der CJ, Buss JE. Curr Opinion Cell Biol. 1992;4:629–636. - PubMed
    1. Schafer WR, Rine J. Annu Rev Genet. 1992;26:209–237. - PubMed
    1. Hancock JF, Magee AI, Chilad JE, Marshall CJ. Cell. 1989;57:1167–1177. - PubMed
    2. Schafer WR, Kim R, Sterne R, Thorner J, Kim SH, Rine J. Science. 1989;245:379–385. - PubMed

Publication types

LinkOut - more resources